Abstract SAT0223 - Table 1 
Baseline characteristics
HDA subgroup/original RCT (n/N) Background: Autoimmune and inflammatory mechanisms could play a significant role in the pathogenesis of pulmonary arterial hypertension (PAH), especially in patients with systemic lupus erythematosus (SLE). The effect of immunosuppressive therapy in the treatment of SLE-associated PAH (SLE-PAH) has not been fully investigated in a large cohort previously. Objectives: We aimed to review the clinical outcomes in patients with SLE-PAH cohort treated with intensive immunosuppressive therapy with or without PAH-targeted therapy. Methods: In this single-center cohort study, 126 patients with SLE-PAH were consecutively enrolled between May 2006 through December 2015. All patients were performed right heart catheriazation to confirm the diagnosis of PAH, and all received intensive immunosuppressive therapy including combination of high-dose glucocorticosteroids and immunosuppressants, such as cyclophosphamide, mycophenolate and calcineurin inhibitors. Baseline demographics, clinical features, laboratory findings, hemodynamic measurements and treatment were analyzed. Kaplan-Meier curves and Cox proportional hazards regression analysis were used to evaluate the role of intensive immunosuppressive therapy. Results: Of the 126 SLE-PAH patients, eighty-two (65.1%) patients received PAH-targeted therapy at baseline. Demographic and clinical characteristics were shown in Table 1 . Survival analysis indicated that responders had a better survival than nonresponders in both with and without PAH-targeted therapy groupPatients with a shorter SLE disease duration (p=0.009) and better baseline pulmonary hemodynamics (mean pulmonary arterial pressure, pulmonary vascular resistance and Cardiac index, p<0.001) were more likely to benefit from immunosuppressive therapy (Table 1) .
Conclusions:
Intensive immunosuppressive therapy markedly improved the long-term outcomes of SLE patients with PAH, especially in the early stage of PAH. Background: CC-220 is a cereblon E3 ligase modulatory compound currently in development for the treatment of Systemic Lupus Erythematosus as well as other autoimmune conditions and multiple myeloma. As a high affinity ligand for cereblon, CC-220 administration results in significant reductions in ikaros (IKZF1) and aiolos (IKZF3), transcription factors which are genetically linked to SLE risk, and are overexpressed in the peripheral blood of SLE patients compared to healthy controls. Objectives: To describe the pharmacokinetics (PK), pharmacodynamics (PD), and the PK-PD relationship of CC-220 in subjects with SLE. Methods: CC-220-SLE-001 is a randomized, double-blinded, placebo-controlled,
